SpePharm is actively seeking to license or acquire products in late-stage development, pre-registration or registration stage, or on the market, to commercialize in Europe.
The corporate strategy of SpePharm is based upon acquiring, or obtaining under license, the European rights to quality and unique products for hospitals and specialists within a limited number of therapeutic fields.
Europe is a market of about 460 million people. However, obtaining the necessary marketing authorizations and launching a new drug in Europe can be a daunting prospect with 27 individual national health, regulatory and reimbursement authorities, 22 languages and 10 different currencies.
SpePharm has the experience and the team to deliver regulatory and marketing solutions across Europe for hospital products. Indeed, SpePharm will have pan-European regulatory and commercial coverage, with clinical development support, including phase IV, and pharmacovigilance.
With a wealth of previous experience and a sales team focused on the European hospital market, SpePharm is ideally positioned to quickly realize the full commercial potential of specialty pharmaceuticals.